Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS

Scheibe, Franziska; Metz, Imke; Radbruch, Helena; Siebert, Eberhard; Wolf, Stefan; Köhnlein, Martin; Harms, Lutz; Meisel, Andreas

doi:10.1212/NXI.0000000000000479

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS

Haupttitel:

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS

Autor*in:

Scheibe, Franziska; Metz, Imke; Radbruch, Helena; Siebert, Eberhard; Wolf, Stefan; Köhnlein, Martin; Harms, Lutz; Meisel, Andreas

Erscheinungsjahr:

2018

Datum der Freigabe:

2019-04-10T07:06:12Z

Abstract:

Currently, 12 cases (including our patient) of autoimmune encephalitis/encephalopathy after daclizumab therapy in MS are known worldwide and led to voluntary withdrawal of marketing authorization for daclizumab by the manufacturer Biogen (press release from European Medicines Agency, 07.03.2018). Our findings suggest that early recognition of DRESS even with CNS manifestations and swift treatment with steroids and/or plasma exchange are essential to improve the longterm outcome.

Identifier:

https://refubium.fu-berlin.de/handle/fub188/24337
http://dx.doi.org/10.17169/refubium-2109

Teil des Identifiers:

ISSN (print): 2332-7812

Sprache:

Englisch

Freie Schlagwörter:

dress syndrome
eosinophilia
daclizumab therapy
MS

DDC-Klassifikation:

610 Medizin und Gesundheit

Publikationstyp:

Wissenschaftlicher Artikel